1 / 1

Rasburicase(Fasturtec)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Formulation:

INJECTION

Validity period:

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

ELITEK® (rasburicase) is a recombinant urate oxidase enzyme specifically designed for the management of tumor lysis syndrome (TLS) in patients with malignancies like leukemia, lymphoma, and solid tumors. It helps lower elevated plasma uric acid levels by enzymatically converting uric acid into a more soluble substance, allantoin, thus preventing complications associated with hyperuricemia. Typically administered as an intravenous infusion, ELITEK® is given daily for a short duration, generally up to five days.

As a targeted therapy for elevated uric acid levels caused by rapid tumor breakdown during cancer treatment, ELITEK® is a vital tool in managing the metabolic complications of tumor lysis syndrome. Careful patient screening for conditions such as G6PD deficiency and close monitoring of treatment are essential for safety.

Generic name

Rasburicase(Fasturtec)

English name

Rasburicase

Alternative Names

Fasturtec

Drug prices

Indications

Elitek® is indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, or solid tumor malignancies receiving anticancer therapy expected to cause tumor lysis syndrome (TLS) and subsequent hyperuricemia.

Therapeutic Target

Catalyzes enzymatic oxidation of uric acid into allantoin, a soluble metabolite, preventing urate nephropathy, acute kidney injury, and TLS complications.

Active Ingredients

Rasburicase (recombinant urate-oxidase).

Dosage form

INJECTION

specifications

NDC 0024-5150-10: 3 vials (1.5 mg each) + 3 ampules (1 mL diluent).

Description

Structure: Tetrameric protein (301 amino acids per subunit; molecular mass ~34 kDa).

Source: Produced by genetically modified Saccharomyces cerevisiae using cDNA from Aspergillus flavus.

Appearance: Sterile, white to off-white lyophilized powder.

Dosage and Administration

Dose: 0.2 mg/kg/day as a 30-minute IV infusion for ≤5 days.

Reconstitution:

1.5 mg vial: 1 mL diluent.

7.5 mg vial: 5 mL diluent.

Do not shake; swirl gently.

Administration:

Dilute in 0.9% NaCl to total 50 mL.

Infuse via separate line; flush with 15 mL saline pre/post-infusion.

Storage: Reconstituted/diluted solutions stored at 2°C–8°C; discard after 24 hours.

CATEGORY NAVIGATION